相关实验视频
Updated: Jan 18, 2026

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
11.9K
大脑缩和认知障碍在初级和二级渐进性多发性硬化症队列-类似的渐进性MS表现型
Bartosz Gajewski1, Małgorzata Siger1, Iwona Karlińska1
1Department of Neurology, Medical University of Lodz, Kopcinskiego 22, 90-153 Lodz, Poland.
International journal of molecular sciences
|September 13, 2025
概括
这项研究揭示了原发性进展性多发性硬化症 (PPMS) 和次发性进展性多发性硬化症 (SPMS) 之间的微妙的MRI和认知差异. 进展性多发性硬化症的恶化符号数字模式测试 (SDMT) 成绩与大脑缩相关,突出显示需要全面的监测工具.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 临床神经学 临床神经学
背景情况:
- 渐进性多发性硬化症 (PMS) 的诊断和监测需要改进的临床工具.
- 了解脑缩和认知障碍在初级渐进性多发性硬化 (PPMS) 和二级渐进性多发性硬化 (SPMS) 中的差异至关重要.
研究的目的:
- 研究基于MRI的脑缩测量与PPMS和SPMS患者的认知功能之间的关系.
- 通过神经成像和认知评估,识别PPMS和SPMS之间疾病进展的潜在差异.
主要方法:
- 这是一项前性研究,涉及39名患者 (20名PPMS,19名SPMS),大约15个月后进行随访.
- 核磁共振分析以测量脑缩分数,包括左丘脑,大脑体,小脑白质 (CWMF) 和胺分数.
- 使用简要视觉空间记忆测试修订,多发性硬化症简要国际认知评估和符号数字模式测试 (SDMT) 的认知评估.
主要成果:
- 与PwPPMS相比,PwSPMS在基线和随访时显示出明显较低的左乳头和身体骨分数.
- 在基线时,PwPPMS的小脑白质分数 (CWMF) 显著降低.
- 在PwSPMS中观察到右胺分数的显著下降;认知得分在各组之间没有显著差异,尽管在整个PMS组和PwPPMS的特定测试中发现了下降.
- 在PwPMS和PwPPMS中,SDMT分数的恶化与白质,小脑和右丘脑分数以及灰质分数 (GMF) 和CWMF的减少相关.
- 在PwSPMS中,Stroop Color和Word测试得分仅与GMF和CGMF相关.
结论:
- 在MRI衍生的脑缩测量和神经心理参数方面,PPMS和SPMS之间存在微妙但显著的差异.
- SDMT性能与各种大脑缩指标之间的相关性强调了SDMT在监测疾病进展中的实用性.
- 为了准确地描述MS在不同临床过程中的疾病进展,需要采用多元组件方法.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K

